Patheon N.V. (NYSE:PTHN) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

8 years ago

Patheon N.V. (NYSE:PTHN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07> Submission of Matters to a Vote of Security
Holders.

The following matters were voted upon and adopted at the 2017
Annual Meeting of Shareholders of Patheon N.V. (the “Company”)
held on March 7, 2017:

1.Appointment of the following persons as directors of our Board:



	Nominee	For	Against	Abstain	Broker Non-Votes
(1a)	James C. Mullen	134,850,968	6,398,027	37,875	503,364

(1b)	Stephan B. Tanda	134,321,524	6,927,471	37,875	503,364

(1c)	Jeffrey P. McMullen	130,706,987	10,541,923	37,960	503,364

(1d)	Gary P. Pisano	134,469,958	6,778,941	37,971	503,364

(1e)	Charles I. Cogut	133,994,909	7,254,001	37,960	503,364

2. Approval, by non-binding vote, of the compensation of the
Company’s named executive officers.



	For	136,604,794
	Against	4,646,141
	Abstain	35,935
	Broker Non-Votes	503,364

3. Approval, by non-binding vote, of the frequency of the advisory
vote on executive compensation.



	1 year	141,050,520
	2 years	5,726
	3 years	195,012
	Abstain	35,612
	Broker Non-Votes	503,364

4. Approval of the adoption of the financial statements for the
fiscal year 2016.



	For	141,550,260
	Against
	Abstain	239,674
	Broker Non-Votes

5. Discharge from liability of the members of our Board of
Directors in respect of the exercise of their duties for the fiscal
year 2016.



	For	141,211,975
	Against	37,323
	Abstain	37,572
	Broker Non-Votes	503,364

6. Appointment of Ernst Young LLP as the Company’s independent
registered public accounting firm and our statutory auditor for
the fiscal year ending October 31, 2017.



	For	141,733,371
	Against	21,516
	Abstain	35,347
	Broker Non-Votes

7. Re-authorization of our Board of Directors to acquire shares
in the Company’s own capital until September 7, 2018.



	For	127,548,666
	Against	14,221,795
	Abstain	19,773
	Broker Non-Votes

8. Re-authorization of our Board of Directors to grant or issue
(rights to acquire) shares until March 7, 2022.



	For	129,168,278
	Against	12,604,679
	Abstain	17,277
	Broker Non-Votes

9. Re-authorization of our Board of Directors to limit or exclude
preemptive rights in respect of a grant or issue of (rights to
acquire) shares.



	For	128,950,523
	Against	12,335,456
	Abstain
	Broker Non-Votes	503,364

10. Authorization of an amendment to the Company’s 2016 Omnibus
Incentive Plan.



	For	131,111,408
	Against	10,139,069
	Abstain	36,393
	Broker Non-Votes	503,364

About Patheon N.V.> (NYSE:PTHN)
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing. Patheon N.V.> (NYSE:PTHN) Recent Trading Information
Patheon N.V.> (NYSE:PTHN) closed its last trading session down -0.01 at 30.94 with 230,616 shares trading hands.